search
Back to results

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

Primary Purpose

Vitiligo

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MKTP with Surgical blade
MKTP with Negative Pressure Instrument
Suction blister grafting without cell dissociation
Sponsored by
University of California, Irvine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitiligo focused on measuring Vitiligo, Melanocyte, Keratinocyte, Transplantation, Procedure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Verified diagnosis of vitiligo by a board-certified dermatologist
  • Candidate for vitiligo treatment as determined by lead researcher
  • Has a 5 cm2 area of vitiligo and an area on the upper thigh that is not affected by the disease
  • Over 18 years of age at the time of signing the informed consent form
  • Ability to understand, abide by and participate in study procedures

Exclusion Criteria:

  • Inability to understand or abide by instructions for participation in study and procedure
  • Pregnant or lactating women
  • Less than 18 years old at the time of signing the informed consent form
  • Current use of tobacco products or within 1 month prior to procedure date
  • History of coagulation disorder, platelet dysfunction disorder, platelet count less than <150,000 platelets per microliter
  • History of poor wound healing or condition that would compromise optimal healing of graft site as deemed by lead researcher
  • History of keloids

Sites / Locations

  • University of California, Irvine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

MKTP with Surgical Blade

MKTP with Negative Pressure Instrument

Suction blister grafting without cell dissociation

Arm Description

The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.

Blister grafting technique with dissociation of the cells was performed in the second arm of the study.

In this arm, transplanting the blisters without dissociation of the cells will be conducted.

Outcomes

Primary Outcome Measures

Percentage of change in the transplanted areas
Percentage of change in the transplanted areas will be evaluated by photography
Percentage of change in the transplanted areas in the transplanted areas
Percentage of change in the transplanted areas will be evaluated by VASI (Vitiligo Area Scoring Index). The minimum value is 0 and maximum value is 100. and higher scores mean worse outcome.

Secondary Outcome Measures

Time of healing
The investigator will evaluate how long it took the patient to heal at both the donor and graft site
Rate of Complication
The investigator will record the rate of complications of the procedure itself.

Full Information

First Posted
April 20, 2020
Last Updated
July 15, 2023
Sponsor
University of California, Irvine
search

1. Study Identification

Unique Protocol Identification Number
NCT04374435
Brief Title
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
Official Title
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Terminated
Why Stopped
The blistering device used for harvesting the third arm was discontinued by the manufacturer.
Study Start Date
September 29, 2017 (Actual)
Primary Completion Date
December 1, 2021 (Actual)
Study Completion Date
May 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Vitiligo is a dermatologic disease characterized by depigmentation of the skin. While the loss of melanocytes observed in vitiligo is driven by the immune system, repigmentation of the skin that occurs during UV light treatment is driven by melanocytes that migrate out of the hair follicle and into the epidermis or the activation of stem cells within the epidermis. Unfortunately, some skin areas affected by vitiligo have very few hair follicle melanocytes and an indeterminate number of epidermal melanocytes and therefore unable to respond to light therapy. This pilot study seeks to examine the relative efficacy of different harvesting methods for the melanocyte keratinocyte transplant procedure (MKTP) in the treatment of vitiligo. In addition, this study will analyze the tissue of excess tissue harvested during the procedure to identify distinct cellular and molecular features of chronic vitiligo. Patients in Dr. Ganesan's clinic at the UCI (University of California, Irvine) Department of Dermatology will be approached for participation in the study. The study will include both men and women and will not be limited by race or ethnicity. The investigators will exclude individuals less than 18 years old for the study as the investigators believe it would be difficult for these subjects to tolerate the melanocyte keratinocyte transplant procedure. Participants will be offered a melanocyte keratinocyte transplant procedure with one of the three different tissue harvesting methods (a blade, suction blister) and the method without dissociation (Cellutome). This study has three arms: MKTP with Surgical Blade MKTP with Negative Pressure Instrument (suction blistering device). Suction blister grafting without cell dissociation utilizing Cellutome (a device used for treating chronic burn wounds)
Detailed Description
In the first arm of the study, a normally pigmented area on the patient was anesthetized with 1% lidocaine with epinephrine. Using a surgical knife, the investigator removed a small portion of the epidermis that is unaffected by vitiligo from a small area (2cm2) on the patient's thigh to obtain donor cells. Epidermis that was harvested with the surgical knife was washed with Lactated Ringer's solution three times and then dissociated using trypsin to separate the cells into a single cell suspension. The recipient area to be grafted was ablated with an Erbium YAG(yttrium aluminum garnet)laser. Half of the dissociated single cells from the donor area (thigh)was then transplanted on to the area affected by vitiligo that the participant is interested in grafting (5 cm2 area). The investigator then evaluated response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography and quantifying the VASI(Vitiligo Area Scoring Index) score. VASI(Vitiligo Area Scoring Index)is the percentage of vitiligo involvement and is calculated in terms of hand units. One hand unit is approximately equivalent to 1% of the total body surface area. In the second arm of the study, the investigator used a minimally invasive procedure (suction blister grafting) to sample the grafted skin and donor skin- this method can separate the epidermis from the dermis without inducing a scar. A normally pigmented area on the upper thigh was anesthetized with 1% lidocaine with epinephrine. Using a suction blister technique, the investigator removed a small portion of the epidermis that was unaffected by vitiligo from a small area (4 cm2 or 0.6 inch cm2) on the patient's thigh to obtain donor cells. Epidermis that was harvested was washed with Lactated Ringer's solution three times and then dissociated using trypsin to separate the cells into a single cell suspension. The recipient areas to be grafted were used to harvest epidermis using a suction blister device. Half of the dissociated single cells from the donor area (thigh) were then transplanted on to the area affected by vitiligo that the patient was interested in grafting (5 cm2 area or 0.7 inch2). The suction blister skin from the recipient sites was simultaneously dissociated into a single cell suspension. A portion of the remainder of the cells (from both the donor and recipient site) was subjected to flow sorting to quantify the populations of melanocytes and keratinocytes and to detailed molecular analysis (single-cell RNA sequencing and histology) to characterize the molecular features of chronic vitiligo. The investigator then evaluated response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography and quantifying the VASI score. This arm of the study is complete. In the third arm of the study, the investigator uses a minimally invasive procedure (suction blister grafting without cell dissociation) to sample the grafted skin and donor skin- this method can separate the epidermis from the dermis without inducing a scar. A normally pigmented area on the upper thigh will be anesthetized with 1% lidocaine with epinephrine. Using an epidermal harvesting system which is a suction blister technique, the investigator will remove multiple small portions (about 128 blisters-1.8 mm in diameter) of the epidermis unaffected by vitiligo from a small normal area (5 cm2 ) on the patient's thigh to obtain donor cells and using a regular negative pressure instrument for removing four samples for histopathological study (two from the vitiligo area and two from the normal donor skin). The epidermis from the donor area (thigh) will then be transplanted on to the area affected by vitiligo that the patient is interested in grafting. Also, the four portions from the normal skin and the recipient site will be sent for the histopathological evaluation. The investigator will then evaluate response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography, quantifying the change in depigmented surface area, and the VASI(Vitiligo Area Scoring Index) score. Also, the investigator will evaluate the two vitiligo samples and two normal skin samples through histopathology to assess where the unique populations of cells identified in their RNA-sequencing analysis are localized (obtained from arm 2). The investigator hypothesizes that his transplant procedure will yield excellent to good repigmentation, resulting in a mean of 60% reduction in surface area (SD=30%) from baseline to 6-month follow up. With a sample size of 5 patients, this study will achieve 90% power to test this hypothesis based on a two-sided paired t-test at p=0.05 significance level. In addition, the investigator will compare the results from the 7 patients harvested using the surgical blade technique (procedure already completed and follow up results pending) with the results from 7 patients harvested with the suction blisters (completed) and seven patients from the newly proposed experimental group (three completed to date).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitiligo
Keywords
Vitiligo, Melanocyte, Keratinocyte, Transplantation, Procedure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
The investigators have completed two arms of the study in sequential study design (each arm has done individually with no random assignment). An exploratory third arm was initiated but then suspended.
Masking
None (Open Label)
Masking Description
The patients were not randomly assigned, rather each arm has been done sequentially with a retrospective comparison of the results.
Allocation
Non-Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MKTP with Surgical Blade
Arm Type
Experimental
Arm Description
The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
Arm Title
MKTP with Negative Pressure Instrument
Arm Type
Experimental
Arm Description
Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
Arm Title
Suction blister grafting without cell dissociation
Arm Type
Experimental
Arm Description
In this arm, transplanting the blisters without dissociation of the cells will be conducted.
Intervention Type
Procedure
Intervention Name(s)
MKTP with Surgical blade
Intervention Description
In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
Intervention Type
Device
Intervention Name(s)
MKTP with Negative Pressure Instrument
Intervention Description
In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
Intervention Type
Device
Intervention Name(s)
Suction blister grafting without cell dissociation
Intervention Description
In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
Primary Outcome Measure Information:
Title
Percentage of change in the transplanted areas
Description
Percentage of change in the transplanted areas will be evaluated by photography
Time Frame
6 months
Title
Percentage of change in the transplanted areas in the transplanted areas
Description
Percentage of change in the transplanted areas will be evaluated by VASI (Vitiligo Area Scoring Index). The minimum value is 0 and maximum value is 100. and higher scores mean worse outcome.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Time of healing
Description
The investigator will evaluate how long it took the patient to heal at both the donor and graft site
Time Frame
6 months
Title
Rate of Complication
Description
The investigator will record the rate of complications of the procedure itself.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Verified diagnosis of vitiligo by a board-certified dermatologist Candidate for vitiligo treatment as determined by lead researcher Has a 5 cm2 area of vitiligo and an area on the upper thigh that is not affected by the disease Over 18 years of age at the time of signing the informed consent form Ability to understand, abide by and participate in study procedures Exclusion Criteria: Inability to understand or abide by instructions for participation in study and procedure Pregnant or lactating women Less than 18 years old at the time of signing the informed consent form Current use of tobacco products or within 1 month prior to procedure date History of coagulation disorder, platelet dysfunction disorder, platelet count less than <150,000 platelets per microliter History of poor wound healing or condition that would compromise optimal healing of graft site as deemed by lead researcher History of keloids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anand K Ganesan, MD, PhD
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92697
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

We'll reach out to this number within 24 hrs